Metastatic HER2-Positive Breast Cancer

Welcome to the Metastatic HER2-Positive Breast Cancer Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Sarah Donahue | UCSF Health

Sarah Donahue, MPH, ANP, AOCNP
Carol Franc Buck Breast Cancer Center
University of California, San Francisco

DESTINY-Breast01

NCCN Breast Cancer Guidelines

Metastatic Breast Cancer Network

ESMO Clinical Practice Guideline: metastatic breast cancer

CLEOPATRA Final OS Data (2013): Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Metastatic HER2-Positive Breast Cancer Resource Center

Interview With Jame Abraham, MD: Metastatic HER2+ Breast Cancer Data at ASCO 2023

DESTINY-Breast01

NCCN Breast Cancer Guidelines

Metastatic Breast Cancer Network

ESMO Clinical Practice Guideline: metastatic breast cancer

CLEOPATRA Final OS Data (2013): Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

BMJ

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial

ESMO Congress 2023 Abstract

386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Current Treatment Options in Oncology

Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer

JAMA Oncology

Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer

OncLive

Frontline zanidatamab plus docetaxel yields antitumor activity, safety in advanced HER2+ breast cancer

Targeted Oncology

Tucatinib plus T-DM1 lowers risk of progression or death in HER2+ mBC

Clinical Breast Cancer

Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

ESMO Open

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Scientific Reports

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

2023 ASCO Annual Meeting Abstract

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

ERBB2 Mutation in HER2-Nonamplified Breast Cancer

Managing Cardiotoxicity Associated With HER2-Targeted Therapy

ER+/PR+ HER2+ Breast Cancer With Brain Metastases